CCM-930

CCM-930 is a lead-optimized small molecule designed to induce translational readthrough of nonsense mutations, also known as premature stop codons. Developed by CCM Biosciences through its CCM Protein Upregulation business unit, the compound was acquired via exclusive licensing from the University of Palermo and the Italian Cystic Fibrosis Foundation. CCM-930 is engineered to treat genetically inherited diseases such as Cystic Fibrosis and Duchenne Muscular Dystrophy by binding to the translational machinery to promote the production of full-length, functional proteins that would otherwise be truncated. Preclinical animal models have demonstrated that CCM-930 possesses a significantly lower cytotoxic profile and improved potency compared to predecessors like ataluren. The drug is currently undergoing IND-enabling studies, with Cystic Fibrosis serving as the lead indication.